Membrane cytosolic translocation of verotoxin A1 subunit in target cells.
In sensitive cells, verotoxin 1 (VT1) utilizes a globotriaosylceramide receptor-dependent retrograde transport pathway from the cell surface to the Golgi/endoplasmic reticulum (ER). The VT1 A subunit (VTA) is an RNA glycanase. Although translocation of VTA from the ER to the cytosol is considered the route for protein synthesis inhibition, cell-based evidence is lacking. A dual-fluorescent-labelled VT1 holotoxin was constructed to simultaneously monitor VTA and VT1 B subunit (VTB) intracellular transport. By confocal microscopy, VTA/VTB subunits remained associated throughout the retrograde transport pathway without cytosolic staining. However, in [125I]VT1-treated cells, the selective cytosolic translocation (4 %) of the activated form of VTA, VTA1, was demonstrated for the first time by monitoring [125I]VTA1 release after plasma membrane permeabilization by streptolysin O (SLO). Lactacystin, a proteasome inhibitor, increased cytosolic VTA1 and enhanced VT1 cytotoxicity. VT1 ER arrival coincided with cytosolic VTA1 detection. Brefeldin A and 16 degrees C, conditions which inhibit VT1 retrograde transport to the Golgi/ER, prevented VTA1 cytosolic translocation; however, these treatments did not completely prevent VT1-induced protein synthesis inhibition. Thus, efficient cytosolic translocation of VTA1 requires transport to the Golgi/ER, but alternative minor escape pathways for protein synthesis inhibition may operate when transport to the Golgi/ER is prevented. Inhibition of protein synthesis was time and dose dependent, and not necessarily a valid index of subsequent cytopathology. Only protein synthesis inhibition following >3 h VT1 exposure correlated with eventual cell cytotoxicity. Extrapolation of translocated cytosolic VTA1 values indicates that about one molecule of translocated VTA1 per cell is sufficient to inhibit protein synthesis and kill a cell.
Tam
Patricia J
PJ
Departments of Laboratory Medicine and Pathobiology, University of Toronto, Canada.|Research Institute, Program in Molecular Structure and Function, The Hospital for Sick Children, Ontario M5G 1X8, Canada.
Lingwood
Clifford A
CA
Department of Biochemistry, University of Toronto, Canada.|Departments of Laboratory Medicine and Pathobiology, University of Toronto, Canada.|Research Institute, Program in Molecular Structure and Function, The Hospital for Sick Children, Ontario M5G 1X8, Canada.
D000111:Acetylcysteine / Q000031:analogs & derivatives / Q000494:pharmacology; D000818:Animals; D020126:Brefeldin A / Q000494:pharmacology; D002462:Cell Membrane / Q000378:metabolism*; D002470:Cell Survival; D002522:Chlorocebus aethiops; D003080:Cold Temperature; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology; D003600:Cytosol / Q000737:chemistry; D004721:Endoplasmic Reticulum / Q000737:chemistry; D006056:Golgi Apparatus / Q000737:chemistry; D018613:Microscopy, Confocal; D014176:Protein Biosynthesis / Q000187:drug effects; D021122:Protein Subunits / Q000378:metabolism; D021381:Protein Transport; D022603:Shiga Toxins / Q000378:metabolism* / Q000633:toxicity; D014709:Vero Cells
D015853:Cysteine Proteinase Inhibitors; D021122:Protein Subunits; D022603:Shiga Toxins; C067713:lactacystin; D020126:Brefeldin A; D000111:Acetylcysteine